Insight Molecular Diagnostics Inc. (IMDX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -1238.5%, revenue growth -53.9% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $4.05M |
| Revenue (TTM) | $0.0B |
| Net Margin | -1238.5% |
| Operating Margin (TTM) | -3011.9% |
| Revenue Growth (YoY) | -53.9% |
| EPS Growth (YoY) | 3.3% |
| FCF Growth (YoY) | 51.6% |
| Price / Sales | 78.77 |
| FCF Yield | -19.3% |
| Altman Z-Score | -26.73 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
IMDX overview · IMDX earnings · IMDX KPIs · IMDX documents · IMDX ownership · IMDX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.